Schedule and Session Descriptors
* Not Approved for ACPE Contact Hours
+ Approved for BCPP Recertification Credit
GB = Grand Ballroom
FL = Florida Ballroom
Sunday, April 19, 2015 (See cpnp.org/2015 for session information and downloads)
Time/Location
7:00 AM - 4:45 PM
GB Foyer
8:00 - 11:15 AM
GB E
Susan Butterworth,
PhD
Event
Registration Desk and Evaluation Stations Open*
Pre-Meeting Workshop: Motivational Interviewing
ACPE #: 0284-0000-15-001-L04-P (Application) (3.0 hours)
Learn and apply Motivational Interviewing (MI), an evidence-based and practical
approach to patient communication that promotes resolution of ambivalence and
behavior change. An extra fee is required to attend.
11:15 AM - 12:45 PM Promotional Product Theater and Lunch
FL
The Other Depression: Identifying and Treating Bipolar Disorder*
Supported by Sunovion
1:00 - 4:30 PM
GB A-D
Resident Programming Track*
1:00-1:30 p.m.
Leading Change
Barbara Wells, PharmD, FCCP, FASHP
Dr. Barbara Wells will get to the nitty-gritty of leadership by describing the challenges involved
in leading change in pharmacy today. Focus will be placed on the role of the pharmacy leader in
the evolving medical community and on practical leadership pearls for the emerging pharmacist.
1:30-2:00 p.m.
CPNP and Leadership: What CPNP Can Do For You
Jerry McKee, PharmD, MS, BCPP
Envision how association involvement can make a difference in your future by learning what
CPNP can provide you in terms of resources, connections, and leadership development.
2:00-3:00 p.m.
Starting From Scratch: Creating a New Practice
Beth DeJongh, PharmD, BCPS; Korin Richardson, PharmD, BCPP; Kelly Gable, PharmD,
BCPP;
Gain practical, first-person insight into the key components of creating a successful new practice.
Learn methods to demonstrate the value of a new practice to promote growth and sustainability.
3:15-4:30 p.m.
Ready, Set, BCPP
Bill Ellis, Board of Pharmacy Specialties; Cynthia Kirkwood, PharmD, BCPP; Beth DeJongh,
PharmD, BCPP; Amber Riesselman, PharmD, BCPP
Representatives from the Board of Pharmacy Specialties (BPS) join us at CPNP 2015 to explain
the criteria that must be met before qualifying to take the board certified psychiatric pharmacy
(BCPP) examination. The content outline domains are described while recently successful
BCPPs outline their preparation strategies. Recertification resources are described to allow soonto-be BCPPs to understand their options upon certification success.
Schedule and Session Descriptors
* Not Approved for ACPE Contact Hours
+ Approved for BCPP Recertification Credit
GB = Grand Ballroom
FL = Florida Ballroom
Sunday, April 19, 2015 (See cpnp.org/2015 for session information and downloads)
Time/Location
1:00 - 4:30 PM
GB E
Event
Student Programming Track*
1:00-2:00 p.m.
Substance Use Disorders and the Healthcare Professional
Speaker Jake Nichols, PharmD, will discuss addiction and how it has impacted him
personally. He will discuss the prevalence of substance abuse among healthcare
providers and identify resources available for those struggling with addiction.
2:00-3:00 p.m.
Pharmacy Practice Specialty Showcase
Students will learn about career opportunities in neuropsychiatric pharmacy. The showcase will
feature four practitioners presenting brief presentations on the specialty areas of substance use
disorders, industry, academic detailing, and primary care.
3:15-4:30 p.m.
Specialty Roundtable Discussions
A variety of experts from differing practice areas will engage in small group discussions on what
it is like to work in the specialty areas featured during the showcase.
Students are encouraged to attend the Student Chapter Meeting (for existing chapters and
interested individuals) from 6:30-7:00 p.m. in the Florida Ballroom and the Student networking
event at Splitsville Lanes in the Channelside Bay Plaza from 7:30-9:30 p.m. (meal provided).
1:00 - 1:15 PM
GB F-J
1:15 - 2:15 PM
GB F-J
George Brown, MD,
DFAPA
BCPP Recertification Opening Remarks*
Pharmacotherapy Issues with Gender Dysphoria+
ACPE #: 0284-0000-15-002-L01-P (Application) (1.0 hours)
Gender Dysphoria has received increasing attention as a treatable condition as part of
the transgender health care equity movement in the United States. This session will
address the epidemiology, diagnostics and barriers to care for individuals with gender dysphoria,
as well as published standards of care to assist pharmacists in creating pharmacotherapeutic
treatment plans for transgender individuals.
Schedule and Session Descriptors
* Not Approved for ACPE Contact Hours
+ Approved for BCPP Recertification Credit
GB = Grand Ballroom
FL = Florida Ballroom
Sunday, April 19, 2015 (See cpnp.org/2015 for session information and downloads)
Time/Location
2:15 - 3:15 PM
GB F-J
Riding the Roller Coaster: Exploring the Controversy Surrounding the Diagnosis and
Treatment of Bipolar Disorder in Children and Adolescents+
ACPE #: 0284-0000-15-003-L01-P (Application) (1.0 hours)
Sandra Mullen,
PharmD, BCPP
Overlapping symptomatology in child and adolescent psychiatry sometimes makes
the diagnosis of bipolar disorder difficult to determine. This session will address the current
controversies regarding the diagnosis of bipolar disorder in children and adolescents,
differentiate the symptoms from other mental health disorders, and present the latest evidence for
the use of pharmacotherapy regimens.
3:15 - 3:30 PM
GB Foyer
Refreshment Break*
3:30 - 4:30 PM
GB F-J
Kenneth Brasfield,
PharmD, BCPP
Medical Mimics: Differential Diagnosis of Psychotic Symptoms+
ACPE #: 0284-0000-15-004-L01-P (Application) (1.0 hours)
When considering a psychiatric diagnosis, one should always be aware of the
possibility of medical conditions contributing to or causing the clinical presentation.
Methods for clinicians to distinguish between psychoses caused by medical conditions versus
psychiatric disorders is to be addressed. Additionally, this session will outline how to assess
patients for medical conditions that can contribute to psychotic symptoms and assist practitioners
in creating both pharmacotherapy and monitoring plans to address psychosis associated with
these conditions.
4:30 - 5:00 PM
FL
5:00 - 6:30 PM
FL
2015 Judith J. Saklad Memorial Award*
Honoring Carla Cobb, PharmD, BCPP
(Refreshments 4:30-4:40)
CPNP Forum on Our Future*
Participate in discussions with the CPNP Board on issues critical to the profession and CPNP as
an organization. Based on your input, CPNP members will facilitate discussion on provider
status and payment for services, expanding demand for psychiatric pharmacy services, and
identifying the optimal neurology and psychiatry curriculum in pharmacy schools. These
discussions will inform CPNP’s strategic discussions and directions.
6:30 - 7:30 PM
Community Gatherings*







Geriatric Care (GERI) Community (Mtg Room 5)
Patient Care Practice Management (PCPM) Community (GB E)
Patient Medication Education Groups (PMEG) Community (GB D)
Research Community (Mtg Room 6)
Residency Program Directors (RPD) Community (GB C)
Residents (GB A-B)
Substance Use Disorders Strategies (SUDS) Community (Mtg Room 1)
Schedule and Session Descriptors
* Not Approved for ACPE Contact Hours
+ Approved for BCPP Recertification Credit
GB = Grand Ballroom
FL = Florida Ballroom
Monday, April 20, 2015 (See cpnp.org/2015 for session information and downloads)
Time/Location
Event
7:00 - 8:00 AM
GB Foyer
Breakfast*
7:00 AM - 4:30 PM
GB Foyer
Registration Desk and Evaluation Stations Open*
8:00 - 8:15 AM
GB F-J
Welcome from CPNP Leadership and Chair*
8:15 - 9:15 AM
GB F-J
The Science of Recovery in Severe Mental Illness
ACPE #: 0284-0000-15-005-L04-P (Knowledge) (1.0 hours)
Lisa Dixon, MD,
MPH
Dr. Lisa Dixon will present a keynote that considers the many dimensions and
definitions of recovery and the importance of a new conceptualization of recovery
involving illness and treatment understanding, empowerment through peers, family support, and
illness management through helping others.
9:15 - 10:15 AM
GB A-E
Poster Session 1 and Break: Research Trainees*
Manned by Authors
10:15 - 11:45 AM
GB F-J
Joseph Parks, MD
Troy Trygstad,
PharmD, MBA, PhD
11:45 AM - 1:45 PM
FL
ACA and Mental Health Care: Can We Deliver?
ACPE #: 0284-0000-15-006-L04-P (Knowledge) (1.5 hours)
The Affordable Care Act (ACA) made mental and behavioral health
treatment 1 of 10 essential benefits required in new insurance policies and
was expected to yield comprehensive coverage of mental illness. However, many of those
seeking treatment are finding shortages of mental health providers and treatment facilities, as
well as gaps in insurance coverage. With the advent of "whole patient" accountable care, a new
set of economic incentives are transforming the larger health care system, and new collaborations
are emerging, often with the desire to provide comprehensive medication management and
coordination services. Drs. Joseph Parks and Troy Trygstad will discuss the impact of the ACA
on mental health care and gaps in service delivery from the perspective of two different health
care eco-systems and their innovative approaches to mental health care delivery.
Symposium with Industry Support and Lunch
The Pharmacists' Impact and Role: Understanding How to Better Diagnose and Treat Patients
with Bipolar Type I Depression
ACPE #: 0284-9999-15-060-L01-P (Knowledge) (1.5 hours)
Supported by Sunovion
Schedule and Session Descriptors
* Not Approved for ACPE Contact Hours
+ Approved for BCPP Recertification Credit
GB = Grand Ballroom
FL = Florida Ballroom
Monday, April 20, 2015 (See cpnp.org/2015 for session information and downloads)
Time/Location
2:00 - 3:00 PM
Concurrent Session
GB F
Event
Track I: Issues of the Day
The Impact of Sleep Disturbances on Depression and Suicide
ACPE #: 0284-0000-15-007-L01-P (Knowledge) (1.0 hours)
Michael Perlis, PhD
Sleep disturbance and insomnia have long been considered to be symptoms of
psychiatric illness. This point of view has shifted and it is now codified in several classification
systems that insomnia is to be considered a disorder in its own right and that when it occurs
concurrently with other disorders, is to be considered a comorbid. This session will provide a
comprehensive overview regarding sleep and depression and sleep and suicide.
2:00 - 3:00 PM
Concurrent Session
Meeting Rooms 5-6
Track II: Research/Networking
Award Finalist Platform Presentations
ACPE #: 0284-0000-15-008-L04-P (Knowledge) (1.0 hours)
Innovative Practices Award Finalists
 2:00-2:15 p.m.: Melissa Brewster, PharmD, BCPS: Development and Implementation
of a Pharmacist-Managed Intranasal Naloxone Distribution Program in a Veterans Affairs
Healthcare Facility and Associated Community Clinics
 2:15-2:30 p.m.: O. Greg Deardorff, PharmD, BCPP: Hematological Clozapine
Monitoring With Finger Prick In A Forensic Inpatient Psychiatric Hospital Setting
Therapeutic Case Report Award Finalists
 2:30-2:45 p.m.: Nicole East, PharmD: Topiramate in the Treatment of Prader-Willi
Syndrome
 2:45-3:00 p.m.: Ian McGrane, PharmD, BCPS: Donepezil-Related Intractable Hiccups:
A Case Report
2:00 - 3:00 PM
Concurrent Session
GB G-J
Track III: BCPP Recertification
Getting High on Knowledge: An Update on Substance Abuse+
ACPE #: 0284-0000-15-009-L04-P (Application) (1.0 hours)
Michael O'Neil,
PharmD
Because of the strong relationship between mental illness and substance abuse, it is
especially important for pharmacists practicing in mental health settings to stay abreast of
substance abuse trends. Mike O’Neil, PharmD, will discuss the impact of the prescription and
illicit substance abuse problem on healthcare systems, including pharmacists in the mental health
setting, as well as obstacles providers in mental health settings may face when treating patients
with substance use disorders.
3:00 - 3:15 PM
GB Foyer
Refreshment Break*
Schedule and Session Descriptors
* Not Approved for ACPE Contact Hours
+ Approved for BCPP Recertification Credit
GB = Grand Ballroom
FL = Florida Ballroom
Monday, April 20, 2015 (See cpnp.org/2015 for session information and downloads)
Time/Location
3:15 - 4:15 PM
Concurrent Session
GB F
Event
Track I: Issues of the Day
Drug Metabolism: Beyond CYP450
ACPE #: 0284-0000-15-010-L01-P (Knowledge) (1.0 hours)
John Markowitz,
PharmD
The CYP450 system is responsible for the metabolism of many psychotropic
medications, and is also involved in a plethora of drug-drug interactions. There are, however,
other enzyme systems responsible for drug metabolism. A good understanding of these enzyme
systems are crucial in recognizing potential drug interactions.
3:15 - 4:30 PM
Concurrent Session
Meeting Rooms 5-6
Track II: Research/Networking
Award Finalist Platform Presentations
ACPE #: 0284-0000-15-011-L04-P (Knowledge) (1.25 hours)
Original Research Award Finalists
 3:15-3:30 p.m.: Kyle Burghardt, PharmD: The Pharmacoepigenetics of Metabolic
Syndrome in Schizophrenia
 3:30-3:45 p.m.: Ian McGrane, PharmD, BCPS: Pharmacogenetics of Cytochrome P450
Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital
Research Trainee Award Finalists
 3:45-4:00 p.m.: Elizabeth Baltenberger, PharmD: Evaluation of Pharmacogenomic
Testing of Patients with Treatment Resistant Depression and Schizophrenia within a VA
Population
 4:00-4:15 p.m.: Katherine Blissit, PharmD, BCPS: Safety of benzodiazepine use among
four patient groups with Post-Traumatic Stress Disorder (PTSD) in a VA Medical Center
 4:15-4:30 p.m.: Lindsey Peters, PharmD: Therapeutic Effects of Intranasal Insulin
Aspart on Cognitive Function in Post-operative Delirium
3:15 - 4:15 PM
Concurrent Session
GB G-J
Bethany DiPaula,
PharmD, BCPP
Track III: BCPP Recertification
The Buprenorphine Debate: An Evidence-Based Look at Current Controversies+
ACPE #: 0284-0000-15-012-L01-P (Application) (1.0 hours)
Buprenorphine is the only partial agonist therapy currently approved for managing
opioid dependence in an office-based setting. Buprenorphine’s monitoring demands, unique
medication properties, and risk for diversion allow for an important role for pharmacists. This
session will discuss the evidence and controversies of buprenorphine/naloxone maintenance
treatment with an emphasis on the psychiatric pharmacist’s role in managing these patients.
4:30 - 6:00 PM
FL
Promotional Product Theater
Balancing Trade-offs in Schizophrenia (SCZ) Therapy: Understanding Compromises That May
Make Some Patients and Caregivers Feel Frustrated*
Supported by Otsuka America Pharmaceutical, Inc.
6:15 - 7:15 PM
GB A-E
Poster Session 2*
Manned by Authors
7:15 - 8:15 PM
GB Foyer
Outgoing President's Reception Honoring Steven Burghart *
Supported by TEVA
Schedule and Session Descriptors
* Not Approved for ACPE Contact Hours
+ Approved for BCPP Recertification Credit
GB = Grand Ballroom
FL = Florida Ballroom
Tuesday, April 21, 2015 (See cpnp.org/2015 for session information and downloads)
Time/Location
Event
7:00 - 8:00 AM
GB Foyer
Breakfast*
7:00 AM - 4:45 PM
GB Foyer
Registration Desk and Evaluation Stations Open*
8:00 - 9:00 AM
GB F-J
Unraveling Torsades de Pointes; Implications for Clinical Practice
ACPE #: 0284-0000-15-013-L01-P (Knowledge) (1.0 hours)
Nancy Allen
LaPointe, PharmD,
MHS, AACC
9:00 - 9:15 AM
GB Foyer
9:15 - 10:15 AM
GB F-J
Michael Friedman,
PhD, MS
10:15 - 11:15 AM
GB F-J
Steven Chen,
PharmD, FASHP,
FCSHP, FNAP
QT prolongation management continues to be a hot topic in psychiatric pharmacy practice, and it
is imperative as the medication experts that we have a basic understanding of this concept and
how the medications we use impact the QT interval. Dr. Allen LaPointe’s presentation will help
psychiatric pharmacy specialists understand the relationship between QT interval prolongations
and its implications/risk of occurrence of torsades de pointes (TdP). She will also review basic
concepts in regard to QT prolongation and QT interval measurements. Finally, an overview of
medications which increase risk of QT prolongation will be discussed and resources for use in
QT prolongation will be presented.
Refreshment Break*
Stigma and Psychiatric Disorders: Understanding and Managing Personal Biases
Jointly Provided by CPNP Foundation and CPNP
ACPE #: 0284-9999-15-014-L04-P (Knowledge) (1.0 hours)
Stigma surrounding psychiatric and substance use disorders can prevent individuals
from seeking care and receiving potentially life-saving treatment. Dr. Friedman will discuss the
prevalence of stigma amongst health care professionals, describe the impact on patient care, and
offer strategies to help health care professionals recognize and manage their own personal biases.
Collaborations to Improve Care: Psychiatric and Ambulatory Care Pharmacists
ACPE #: 0284-0000-15-015-L04-P (Knowledge) (1.0 hours)
Pharmacists are increasingly being used as providers in ambulatory care and clinic
settings and can be tasked with treatment of psychiatric conditions. Collaboration
between psychiatric and ambulatory care pharmacists can provide benefit to patients, providers,
and clinics. Dr. Steven Chen will discuss deficits in providing mental health services, the
resulting cost burden to primary care clinics, how to establish an effective practice model for
integrating ambulatory care and psychiatric pharmacists into primary care clinics, and how to
document the collaborative interactions.
Schedule and Session Descriptors
* Not Approved for ACPE Contact Hours
+ Approved for BCPP Recertification Credit
GB = Grand Ballroom
FL = Florida Ballroom
Tuesday, April 21, 2015 (See cpnp.org/2015 for session information and downloads)
Time/Location
Event
11:15 AM - 12:45 PM Promotional Product Theater and Lunch
FL
Acute Treatment of Agitation Associated With Schizophrenia or Bipolar I Disorder*
Supported by TEVA
1:00 - 2:00 PM
Concurrent Session
GB F-J
Cindy O'Bryant,
PharmD, BCOP,
FCCP
1:00 - 2:00 PM
Concurrent Session
GB E
Susan Fagan,
PharmD, BCPS,
FCCP
1:00 - 2:00 PM
Concurrent Session
GB A-D
Track I: Ambulatory Care
Approaches to Treating Depression in Patients with Cancer
ACPE #: 0284-0000-15-016-L01-P (Knowledge) (1.0 hours)
Up to a quarter of patients with cancer suffer from depression that may go
unrecognized, affecting their quality of life. Confounding matters, many of the symptoms of
depression can be often confused with side effects of cancer treatments. This session will review
the literature related to depression in cancer patients and examine ways to distinguish depressive
symptoms from disease or treatment related symptoms while identifying strategies for
implementing appropriate therapy.
Track II: Neurology
Update on Stroke Management: A Primary Care Perspective
ACPE #: 0284-0000-15-017-L01-P (Knowledge) (1.0 hours)
This session will provide a summary of the most recently updated, evidence-based
guidelines and recommendations on the prevention of secondary stroke, screening assessments,
and new therapies for prevention. Decision points for control of risk factors and selection of
therapies will be discussed.
Track III: Research
Pipeline Medications*
The purpose of the Pipeline session is to present the very latest information about new CNS
compounds to attendees at the CPNP Annual Meeting with the goal being that attendees will
learn about the most promising agents in the specialty drug pipeline.
 2:04-2:22 p.m.: Carolyn McMicken, PsyD: Idalopirdine: A Novel 5-HT6 Receptor
Antagonist in Development for the Treatment of Alzheimer’s Disease
 2:23-2:41 p.m.: Andrew Hsieh, PharmD: A Phase 2b, Randomized, Double-blind,
Placebo-controlled, 12-week Study of Encenicline, an α7 Nicotinic Acetylcholine
Receptor Partial Agonist, for Cognitive Impairment in Patients with Schizophrenia
 2:42-3:00 p.m.: Candace Andersson, PhD: Development Update on Pimavanserin, a
Novel 5HT-2A Receptor Inverse Agonist
2:00 - 2:15 PM
GB Foyer
Refreshment Break*
Schedule and Session Descriptors
* Not Approved for ACPE Contact Hours
+ Approved for BCPP Recertification Credit
GB = Grand Ballroom
FL = Florida Ballroom
Tuesday, April 21, 2015 (See cpnp.org/2015 for session information and downloads)
Time/Location
2:15 - 3:15 PM
Concurrent Session
GB F-J
Andy Mendenhall,
MD
2:15 - 3:15 PM
Concurrent Session
GB E
Event
Track I: Ambulatory Care
Pain Management of Co-Occurring Addiction and Chronic Pain
ACPE #: 0284-0000-15-018-L01-P (Knowledge) (1.0 hours)
Prescription opioid misuse and addiction among chronic pain patients are emerging
public health concerns due to dramatic increases in deaths related to overdoses. The use of
opioids in the chronic non-cancer pain patient population is controversial, even more so for
patients with a history of addiction. Treatment strategies include maintenance buprenorphine use
and interdisciplinary pain rehabilitation programs. Evidence suggests addiction and chronic pain
are interrelated and effective treatment for both is necessary for successful outcomes.
Track II: Neurology
Traumatic Brain Injury: A Hard Hitting Problem
ACPE #: 0284-0000-15-019-L01-P (Knowledge) (1.0 hours)
Understanding the expanse of influence of TBI on psychiatric patient care continues
Kimberly Arlinghaus, to be a challenge. Individuals with TBI have been known to experience a wide variety of
MD
symptoms including depression, mania, anxiety, headache, psychosis, aggression, apathy, poor
attention, memory difficulties, and poor executive functioning. In this session, Dr. Arlinghaus
will define traumatic brain injury, explain the scope of issues experienced in TBI, and discuss
treatment options for cognitive and behavioral symptoms related to TBI.
3:30 - 4:30 PM
GB F-J
Clinical Pearls
ACPE #: 0284-0000-15-020-L01-P (Knowledge)
(1.0 hours)
 4:32-4:46 PM: Brittany Finocchio, PharmD: Adjunctive Estrogen Therapy in
Schizophrenia
 4:46-5:00 PM: Shauna Garris, PharmD, BCPS: Use of Zolpidem for Catatonia
 5:00-5:14 PM: Jonathan Lister, PharmD, BCPS: Treatment Options for ClozapineInduced Dyscrasias
 5:14-5:28 PM: Korin Richardson, PharmD, BCPP: The Danger Zone: Where
Benzodiazepines and Opiates Meet
4:45 - 5:45 PM
Learning Labs*
 Clinical Pearls Deep Dive (GB F-J)
 Provider Status and Payment for Pharmacists' Services (Meeting Rooms 5-6)
 Veterans Affairs Pharmacists Discussion (GB E)
6:00 - 7:30 PM
GB A-C
Industry Supported Event
Meet the Sunovion Medical Affairs Team*
Supported by Sunovion
Wednesday, April 22, 2015 (See cpnp.org/2015 for session information and downloads)
Time/Location
Event
7:00 - 8:00 AM
(Meet at 6:50)
Tampa Marriott
Waterside Terrace
NAMI Walk*
7:45 - 8:45 AM
GB Foyer
Breakfast*
8:00 AM - 12:00 PM
GB Foyer
Registration Desk and Evaluation Stations Open (evaluation stations close at 11:00 a.m.)*
8:20 - 8:30 AM
GB F-J
NAMI Walk Donation Presentation by the CPNP Foundation*
8:30 - 9:30 AM
GB F-J
Medications Used to Treat Mood Disorders in Pregnancy: Controversies and Clinical
Dilemmas
ACPE #: 0284-0000-15-021-L01-P (Knowledge) (1.0 hours)
Marlene Freeman,
MD
Dr. Marlene Freeman will discuss current clinical controversies surrounding
psychiatric medications used in the treatment of mood disorders during pregnancy. She will also
discuss the risk versus benefit of using psychiatric medications in women of childbearing age
and pregnancy.
9:30 - 10:00 AM
GB Foyer
Refreshment Break*
10:00 - 11:00 AM
GB F-J
Larry Ereshefsky,
PharmD, BCPP,
FCCP
Brett English,
PharmD, PhD
11:00 AM - 12:00 PM
GB F-J
Diana Perkins, MD,
MPH
New Approaches to Drug Development: Neurocircuitry Based Strategies
Inspired by the Research Domain Criteria (RDoC) Initiative
ACPE #: 0284-0000-15-022-L04-P (Knowledge) (1.0 hours)
This presentation will focus on Early Drug Development describing novel
approaches and technologies to enhance Phase I studies to inform & de-risk drug development to
support Proof of Concept trials. An exciting new approach is the growing adoption of a Research
Domain Criteria (NIMH initiative) influenced approach to drug development. The prioritization
of behavioral, biomarker, and other neurophysiological measures that demonstrate engagement
in neurocircuitry of relevance, can bring greater sensitivity to detect signal than typical
behavioral measures (i.e., rating scales). The implications for drug development will be
discussed in the context of a data driven presentation demonstrating these new technologies
(quantitative EEG, Event Related Potential, fMRI, and cerebral spinal fluid sampling).
Where Do We Stand with the Psychosis Risk Syndrome?
ACPE #: 0284-0000-15-023-L01-P (Knowledge) (1.0 hours)
This session will provide an overview of the psychosis risk syndrome, describe
initiatives and emerging data on the risk for psychosis, and discuss potential
treatment strategies to prevent conversion to psychosis.